Skip to main content

Table 1 Baseline characteristics of all participants and by intervention group

From: Effects of protein-rich nutritional supplementation and bisphosphonates on body composition, handgrip strength and health-related quality of life after hip fracture: a 12-month randomized controlled study

 

All patients (n = 79)

Group N (n = 26)

Group B (n = 28)

Group C (n = 25)

Age, mean (SD)

79 (9)

81 (8)

80 (9)

78 (11)

Age, median (range)

81 (61–96)

82 (62–93)

82 (63–94)

75 (61–96)

Gender, female n (%)

    

 Women

56 (71)

19 (73)

18 (64)

19 (76)

 Men

23 (29)

7 (27)

10 (36)

6 (24)

Type of fracture n (%)

    

 Femoral neck

33 (42)

10 (38)

12 (43)

11 (44)

 Trochanteric

46 (58)

16 (62)

16 (57)

14 (56)

Surgical method n (%)

    

 Internal fixation

69 (87)

23 (88)

25 (89)

21 (84)

 Arthroplasty

10 (13)

3 (12)

3 (11)

4 (16)

Time to surgery n (%)

    

 Within 24 hours

43 (54)

13 (16)

17 (22)

13 (16)

  > 24 to 48 hours

36 (46)

13 (16)

11 (14)

12 (15)

ASA 1–2 n (%)

60 (76)

20 (25)

22 (28)

18 (23)

ASA 3–4 n (%)

19 (24)

6 (9)

6 (8)

7 (8)

Body mass,kg mean (SD)

63.0 (12.3)

61.4 (9.8)

66.9 (13.3)

60.2 (12.8)

 Women

58.7 (10.0)

60.2 (9.8)

60.7 (10.0)

55.4 (9.8)

 Men

73.3 (11.3)

64.7 (9.5)

78.2 (11.2)

75.4 (8.7)

BMI, kg/m2 mean (SD)

23.0 (3.0)

22.7 (3.4)

24.0 (2.9)

22.4 (2.6)

 Women

22.8 (3.1)

23.0 (3.5)

23.9 (3.1)

21.7 (2.5)

 Men

23.5 (2.8)

21.8 (3.3)

24.1 (2.8)

24.5 (1.2)

FFMI, kg/m2 mean (SD)

16.1 (2.0)

15.6 (1.9)

16.8 (2.0)

16.0 (2.0)

 Women

15.3 (1.4)

15.0 (1.6)

15.9 (1.4)

15.1 (1.0)

 Men

18.1 (2.0)

17.1 (2.0)

18.3 (2.0)

18.8 (1.7)

FMI, kg/m2 mean (SD)

6.9 (2.5)

7.1 (2.9)

7.2 (2.4)

6.4 (2.0)

 Women

7.5 (2.5)

8.0 (2.6)

8.0 (2.4)

6.6 (2.2)

 Men

5.5 (1.8)

4.8 (2.4)

5.8 (1.7)

5.7 (1.1)

aLMI, kg/m2

6.2 (0.9)

6.0 (0.8)

6.5 (0.9)

6.2 (1.0)

 Women

5.9 (0.7)

5.8 (0.8)

6.1 (0.6)

5.8 (0.6)

 Men

7.0 (1.0)

6.6 (80.8)

7.1 (1.0)

7.5 (0.9)

Handgrip strength, kg, median (range)

20 (6–64)

20 (6–63)

22 (6–64)

20 (8–58)

 Women

18 (6–38)

18 (6–32)

18 (6–28)

17 (8–38)

 Men

36 (20–64)

24 (20–33)

45 (28–64)

40 (23–58)

EQ-5Dindex mean, (SD)

0.85 (0.21)

0.84 (0.22)

0.84 (0.25)

0.88 (0.12)

S-IGF-I, μg/L, median, (range)

87 (27–239)

72 (30–169)

93 (30–207)

87 (27–239)

S-IGF-I age matched SD- score

−0.6

−1.1

−0.1

−0.8

P-Alb g/L, median, (range)

34 (26–44)

34 (27–42)

34 (26–44)

34 (26–44)

B-Hbg g/L, median, (range)

124 (90–156)

124 (97–149)

128 (103–156)

119 (90–153)

S-CRP mg/L, median (range)

3 (0–257)

4 (0–136)

2 (0–253)

8 (0–257)

P-Creatinine μmol/L,median, (range)

71 (37–174)

69 (37–136)

74 (47–118)

71 (49–174)

S-ALAT, μkat/L, median, (range)

0.41 (0.10–8.82)

0.36 (0.10–8.82)

0.40 (0.12–3.02)

0.45 (0.19–1.57)

S-ASAT, μkat/L, median, (range)

0.65 (0.22–2.42)

0.66 (0.23–1.61)

0.62 (0.35–2.42)

0.60 (0.22–1.60)

S-TSH, mE/L, median (range)

1.5 (0.1–9.3)

1.7 (0.4–8.5)

1.4 (0.8–8.5)

1.4 (0.4–9.3)

  1. Group N, received nutritional supplementation, bisphosphonate, calcium and vitamin D3; B, received bisphosphonate, calcium and vitamin D; C, controls, treated with calcium and vitamin D. Body mass (lean mass, fat mass and bone mineral content); ASA, the American Society of Anesthesiologists classification; BMI, body mass index; FFMI, fat free mass index; FMI, fat mass index; aLMI, appendicular lean mass index; EQ-5Dindex, the 5-Dimentional Scale of the HRQoL; S-IGF-I, serum-insulin growth factor-I; P-Alb, plasma-albumin; B-Hbg, blood-Hemoglobin; S-CRP, serum-C-reactive protein; P-creatinine, plasma creatinine; S-ALT, serum alanine aminotransferase; S-AST, serum aspartate aminotransferase; S-TSH, serum thyroid-stimulating hormone. Baseline characteristics showed no significant difference between the groups
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us